The First Pharmaceutical Company for Protection of Human Rights in Clinical Research
- Details
- Category: Pfizer

Pfizer Development Pipeline Shows Advances In High-Priority Disease Areas
- Details
- Category: Pfizer

GSK submits Tyverb®/Tykerb® for first-line treatment of metastatic breast cancer in Europe, US
- Details
- Category: GlaxoSmithKline

Significantly More Patients With Cardiovascular Disease Quit Smoking Using Chantix/Champix®
- Details
- Category: Pfizer

Bayer Crop Science and the French research organization CNRS intensify collaboration
- Details
- Category: Bayer

Novartis makes an open offer to increase stake in Novartis India Ltd.
- Details
- Category: Novartis

HemCon Medical Technologies, Inc. Announces Improved Results from Live Nail Infection Study
- Details
- Category: Clinical Trials
HemCon has announced results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of Onychomycosis, the most common type of fungal nail infection. The studies were conducted as part of HemCon's continued program of development for a formulation based on its newest proprietary Mycosinate™ platform technology.
More Pharma News ...
- EMERFLU®, pandemic influenza vaccine for humans, approved in Australia
- Glivec® recommended for use in Europe as first post-surgery treatment for GIST
- New image of therapy for erectile difficulties
- Merck KGaA and Fast Forward, LLC Announce Collaboration
- U.S. Patent & Trademark Office Grants Reissue Patent Relating to Lipitor
- Roche acquires innovatis AG to complement its product portfolio
- The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent